Stephan Ortiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Stephan Ortiz has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Esther Garcia Gil
Almirall, SA, Barcelona, Spain
2 shared publicationsJosep M. Jansat
Almirall, SA, Barcelona, Spain
2 shared publicationsStephen Flach
Covance Clinical Research Unit, Inc, Madison, Wisconsin
2 shared publicationsCynthia Caracta
Forest Research Institute, Jersey City, New Jersey
1 shared publicationCynthia F. Caracta
Forest Research Institute, Inc. Jersey City New Jersey USA
1 shared publicationFanying Li
Forest Research Institute, Inc. Jersey City New Jersey USA
1 shared publication
Latest Publications
- 1 June 2012
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 52 (6) , 819-827
Safety and Tolerability of Aclidinium Administered Intravenously and Absolute Bioavailability of Inhaled Aclidinium in Healthy Male Participants
Aclidinium bromide is a long‐acting muscarinic antagonist in development for chronic obstructive pulmonary disease treatment. This 2‐part, phase I study evaluated the safety and tolerability of single ascending intravenous (IV) doses of aclidinium to determine its maximum tolerated dose (MTD; part I) and its absolute bioavailability (part II). Healthy male participants (N = 24) were randomized (1:1) in each part: 3‐period crossover, placebo‐controlled, single‐ascending, alternating IV doses of aclidinium (25–400 μg) in part I and 2‐period crossover, single‐alternating IV and inhaled doses of aclidinium (200 μg) in part II. A ≥7‐day washout separated treatment periods. Pharmacokinetic data were collected in both parts. Following IV or inhaled aclidinium, time to reach maximum plasma concentration following drug administration (tmax) was 5 to 7 minutes for all doses. After maximum plasma drug concentration (Cmax), aclidinium was rapidly cleared from plasma. Aclidinium absolute bioavailability was <5% following a single inhaled 200‐μg dose. Urinary excretion of unchanged aclidinium was very low, with a greater amount of inactive metabolites excreted compared with aclidinium, all of which were recovered within 12 hours postdose. The MTD following IV administration was not reached; all single IV (25–400 μg) and inhaled doses (200 μg) were well tolerated. In conclusion, the low and short‐lived bioavailability of aclidinium and the low incidence of systemic side effects contribute to its positive safety and tolerability profile.
- 1 June 2012
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 52 (6) , 819-827
Safety and Tolerability of Aclidinium Administered Intravenously and Absolute Bioavailability of Inhaled Aclidinium in Healthy Male Participants
Aclidinium bromide is a long‐acting muscarinic antagonist in development for chronic obstructive pulmonary disease treatment. This 2‐part, phase I study evaluated the safety and tolerability of single ascending intravenous (IV) doses of aclidinium to determine its maximum tolerated dose (MTD; part I) and its absolute bioavailability (part II). Healthy male participants (N = 24) were randomized (1:1) in each part: 3‐period crossover, placebo‐controlled, single‐ascending, alternating IV doses of aclidinium (25–400 μg) in part I and 2‐period crossover, single‐alternating IV and inhaled doses of aclidinium (200 μg) in part II. A ≥7‐day washout separated treatment periods. Pharmacokinetic data were collected in both parts. Following IV or inhaled aclidinium, time to reach maximum plasma concentration following drug administration (tmax) was 5 to 7 minutes for all doses. After maximum plasma drug concentration (Cmax), aclidinium was rapidly cleared from plasma. Aclidinium absolute bioavailability was <5% following a single inhaled 200‐μg dose. Urinary excretion of unchanged aclidinium was very low, with a greater amount of inactive metabolites excreted compared with aclidinium, all of which were recovered within 12 hours postdose. The MTD following IV administration was not reached; all single IV (25–400 μg) and inhaled doses (200 μg) were well tolerated. In conclusion, the low and short‐lived bioavailability of aclidinium and the low incidence of systemic side effects contribute to its positive safety and tolerability profile.
- 1 January 2012
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 33 (1) , 39-45
Mass balance and metabolism of aclidinium bromide following intravenous administration of [14C]‐aclidinium bromide in healthy subjects
Aclidinium bromide is a novel, inhaled long‐acting muscarinic antagonist with low systemic activity developed for the treatment of COPD. It is an ester compound rapidly hydrolysed in plasma into inactive alcohol and acid metabolites. In this Phase I, open‐label study, the rates and routes of elimination of radioactivity following intravenous administration of [14 C]‐aclidinium bromide were determined. The metabolites of aclidinium were also characterized and identified in plasma and excreta. Twelve healthy males were randomized (1:1) to receive a single intravenous 400 µg dose of [phenyl‐U‐14 C]‐ or [glycolyl‐U‐14 C]‐aclidinium bromide (via 5 min infusion) to label alcohol or acid metabolites of aclidinium, respectively. Safety and tolerability were assessed over a 9‐day period. Following intravenous administration, the parent compound was rapidly hydrolysed into its acid and alcohol metabolites. Primary excretion routes for [phenyl‐U‐14 C]‐ and [glycolyl‐U‐14 C]‐aclidinium were renal (urine: 65% and 54%, respectively; feces: 33% and 20%, respectively), with 1% excreted as unchanged aclidinium. A total of three treatment‐emergent adverse events in two subjects were reported and were related to infusion site pain. Overall, aclidinium is rapidly hydrolysed into two main metabolites, which are predominantly excreted in urine. Aclidinium bromide 400 µg administered intravenously was safe and well tolerated in healthy subjects. Copyright © 2012 John Wiley & Sons, Ltd.
- 1 January 2012
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 33 (1) , 39-45
Mass balance and metabolism of aclidinium bromide following intravenous administration of [14C]‐aclidinium bromide in healthy subjects
Aclidinium bromide is a novel, inhaled long‐acting muscarinic antagonist with low systemic activity developed for the treatment of COPD. It is an ester compound rapidly hydrolysed in plasma into inactive alcohol and acid metabolites. In this Phase I, open‐label study, the rates and routes of elimination of radioactivity following intravenous administration of [14 C]‐aclidinium bromide were determined. The metabolites of aclidinium were also characterized and identified in plasma and excreta. Twelve healthy males were randomized (1:1) to receive a single intravenous 400 µg dose of [phenyl‐U‐14 C]‐ or [glycolyl‐U‐14 C]‐aclidinium bromide (via 5 min infusion) to label alcohol or acid metabolites of aclidinium, respectively. Safety and tolerability were assessed over a 9‐day period. Following intravenous administration, the parent compound was rapidly hydrolysed into its acid and alcohol metabolites. Primary excretion routes for [phenyl‐U‐14 C]‐ and [glycolyl‐U‐14 C]‐aclidinium were renal (urine: 65% and 54%, respectively; feces: 33% and 20%, respectively), with 1% excreted as unchanged aclidinium. A total of three treatment‐emergent adverse events in two subjects were reported and were related to infusion site pain. Overall, aclidinium is rapidly hydrolysed into two main metabolites, which are predominantly excreted in urine. Aclidinium bromide 400 µg administered intravenously was safe and well tolerated in healthy subjects. Copyright © 2012 John Wiley & Sons, Ltd.